We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Partners to Establish Center for Medical Cannabis R&D in Israel

By LabMedica International staff writers
Posted on 20 Mar 2016
Two Israeli-based biotechnology firms have agreed to establish a center to concentrate research, development, and commercialization of medical marihuana and other cannabis products.

The partners are iCAN- Israel Cannabis (Beit Shemesh, Israel) and Breath of Life Pharma (BOL Pharma; Israel). More...
BOL Pharma, established in 2008, is regarded as Israel’s leading medical cannabis drug development firm, while iCAN- Israel Cannabis is actively engaged in identifying and accelerating cannabis technologies in Israel.

The primary objectives of the new center will be to strengthen research and development of new cannabis-related technologies with the goal of successful commercialization. The center will serve as an incubator for cannabis innovation as well as a validator of cannabis-based medicines and agricultural-technological and topical product development based on stringent guidelines and standards.

Dr. Tamir Gedo, CEO of BOL Pharma, said, “BOL greenhouses allow developers to use the professional services and knowledge of BOL Pharma, in order to produce strains, improve growing conditions, master extraction, formulation, and production of materials under GMP conditions, and ultimately to enable companies to commercialize their research and go to market. Together with iCAN- Israel Cannabis, we will incubate companies from all over the world to test and validate medical products for the global cannabis market.”

Saul Kaye, CEO of iCAN- Israel Cannabis, said “We are thrilled to partner with BOL Pharma and provide a global incubator and proving ground for cannabis technology. We are confident our partnership will enable the most promising start-ups and innovators in Israel and abroad, to create world class products for the global cannabis economy.”

Related Links:

iCAN- Israel Cannabis
Breath of Life Pharma 



Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
New
Automated Coagulation Analyzer
Hemolumi H6
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The updated CRC screening guidance adds a stool RNA test and an updated stool DNA test to the menu of preferred options (image credit: Adobe Stock)

Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests

Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more

Immunology

view channel
Image: Study design for analysis of monocyte phenotype, function, and metabolism (Gráinne Jameson et al., Journal of Infection (2026). DOI: 10.1016/j.jinf.2026.106755)

Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response

Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.